Hind.Bio Science (532041)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Reported ROE of 17.35% looks attractive on paper and indicates some profitability on a small equity base.
• Profit growth of 300% gives a PEG of 0.19, pointing to apparent momentum if the earnings are organic and repeatable.
• Piotroski F-score of 6/9 is a passable signal of improving fundamentals.
• Tiny ₹8 Cr market cap leaves room for a large percentage upside if a genuine business model emerges.

Concerns

• Latest quarter sales and net profit are both ₹0 Cr, so there is no visible operating engine.
• Valuation is expensive: P/E 55.71 and P/B 10.96 against book value of just ₹0.74.
• ROCE of only 2.95% shows poor returns on capital employed; the ROE is flattered by a thin equity base.
• Promoter holding is N/A and FairStock Score is N/A, creating a serious transparency problem.

AI Analysis

At ₹8.11, Hind.Bio Science is a ₹8-crore microcap that offers almost nothing a Graham investor can value. The latest quarter reports zero sales and zero net profit, while reported sales growth is flat. A 300% profit growth number and a PEG of 0.19 look eye-catching, but with no current revenue, that profit is a tiny, unreliable base — likely a base effect or non-operating item, not durable compounding. The P/E of 55.71 and P/B of 10.96 against a book value of just ₹0.74 mean the market is already paying a heavy price for hope. ROE of 17.35% may sound nice, but ROCE of only 2.95% exposes the underlying business: on capital employed, returns are almost negligible. The Piotroski F-score of 6/9 is acceptable, but it cannot compensate for zero sales and undisclosed promoter holding. The FairStock score is N/A because of insufficient data, and that itself is a warning. There is no dividend, so every rupee of return must come from price appreciation — not a margin of safety. In the 52-week range of ₹5.00-₹9.92, the stock is trading in the upper half, so I am not being offered a distressed price. This is not a wonderful business with a moat; it is a speculative shell with a software-products label and a bio-science name. As Graham said, price is what you pay, value is what you get. I see no clear value here, only a small market cap and hope. Without meaningful revenue, higher return on capital, and proper disclosure, I cannot call it an investment. I would rather wait for a margin of safety, or pass altogether. For an Indian retail investor, this belongs in the 'too hard' pile unless the company starts proving itself with actual numbers.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer